Last reviewed 2026-04-23 · How we verify

TH9507

TH9507 is a recombinant human growth hormone (hGH) analog designed to stimulate growth and metabolic function in patients with growth hormone deficiency or wasting conditions.

TH9507 is a recombinant human growth hormone (hGH) analog designed to stimulate growth and metabolic function in patients with growth hormone deficiency or wasting conditions. Used for HIV-associated lipodystrophy.

At a glance

Mechanism of action

TH9507 is a long-acting growth hormone therapeutic that binds to growth hormone receptors to promote anabolic effects, including increased lean body mass, improved metabolism, and enhanced physical function. It is being developed as a treatment for HIV-associated lipodystrophy and other conditions characterized by abnormal fat distribution and metabolic dysfunction.

Approved indications

• HIV-associated lipodystrophy

Common side effects

• Injection site reactions
• Carpal tunnel syndrome
• Arthralgia
• Edema
• Hyperglycemia

Key clinical trials

• Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
• Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons (PHASE2)
• Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk (PHASE2)
• Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury (PHASE2)
• Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (PHASE2)
• Body Composition and Adipose Tissue in HIV (PHASE4)
• TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (PHASE3)
• Growth Hormone Dynamics and Cardiac Steatosis in HIV

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.